16 October, 2025
Omnix Medical Secures $25 Million Series C to Tackle Antimicrobial Resistance
The Israeli biotech company announced the closing of a $25M Series C funding round aimed at accelerating clinical development of its novel treatment for drug-resistant infections. The funding will enable Omnix Medical to advance toward later-stage trials and expand its impact in the global fight against antimicrobial resistance.
We’re proud to see the company’s continued growth and dedication to improving global health!